← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
XBIT
XBiotech Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$2.19
Model IV—
P/IV—
Market implies +31.0%/yr vs model +15.0% · above model
XBPEW
XBP Global Holdings, Inc.
Valuation N/A
Technology Risk 44 · Elevated
Price$0.03
Model IV—
P/IV—
Market implies -50.0%/yr vs model +12.0% · below model
XCH
XCHG Ltd
Valuation N/A
Technology
Price$3.14
Model IV—
P/IV—
Market implies +93.8%/yr vs model +2.0% · above model
XCUR
EXICURE, INC.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.31
Model IV—
P/IV—
Market implies +28.7%/yr vs model +15.0% · above model
XENE
Xenon Pharmaceuticals Inc.
Valuation N/A
Healthcare Risk 41 · Elevated
Price$58.65
Model IV—
P/IV—
Market implies +111.3%/yr vs model +2.0% · above model
XFOR
X4 Pharmaceuticals, Inc
Valuation N/A
Healthcare Risk 48 · Elevated
Price$3.62
Model IV—
P/IV—
Market implies +38.9%/yr vs model +15.0% · above model
XHG
XChange TEC.INC
Valuation N/A
Financial Services Risk 27 · Moderate
Price$3.02
Model IV—
P/IV—
Market implies +137.9%/yr vs model +2.0% · above model
XHLD
TEN Holdings, Inc.
Valuation N/A
Technology Risk 31 · Moderate
Price$12.53
Model IV—
P/IV—
Market implies +64.2%/yr vs model +2.0% · above model
XMAX
XMax Inc.
Valuation N/A
Consumer Cyclical Risk 38 · Moderate
Price$8.55
Model IV—
P/IV—
Market implies +19.4%/yr vs model +7.4% · above model
XNCR
Xencor Inc
Valuation N/A
Healthcare Risk 42 · Elevated
Price$24.41
Model IV—
P/IV—
Market implies +65.5%/yr vs model +2.0% · above model
XNET
Xunlei Ltd
Valuation N/A
Technology Risk 33 · Moderate
Price$4.90
Model IV—
P/IV—
Market implies +34.3%/yr vs model +17.6% · above model
XOMA
XOMA Royalty Corp
Valuation N/A
Healthcare Risk 54 · Elevated
Price$40.17
Model IV—
P/IV—
Market implies +69.6%/yr vs model +2.0% · above model
XOMAO
XOMA Royalty Corp
Valuation N/A
Healthcare Risk 42 · Elevated
Price$25.00
Model IV—
P/IV—
Market implies +72.6%/yr vs model +2.0% · above model
XOMAP
XOMA Royalty Corp
Valuation N/A
Healthcare Risk 53 · Elevated
Price$24.98
Model IV—
P/IV—
Market implies +37.2%/yr vs model +2.0% · above model
XOS
Xos, Inc.
Valuation N/A
Consumer Cyclical Risk 31 · Moderate
Price$2.71
Model IV—
P/IV—
Market implies +49.3%/yr vs model +8.0% · above model
XPO
XPO, Inc.
Valuation N/A
Industrials Risk 51 · Elevated
Price$182.18
Model IV—
P/IV—
Market implies +32.3%/yr vs model +4.0% · above model
XRN
Chiron Real Estate Inc.
Valuation N/A
Financial Services Risk 58 · Elevated
Price$35.99
Model IV—
P/IV—
Limited data — see page
XRXDW
Xerox Holdings Corp
Valuation N/A
Technology Risk 54 · Elevated
Price$0.35
Model IV—
P/IV—
Market implies -50.0%/yr vs model +7.6% · below model
XWEL
XWELL, Inc.
Valuation N/A
Consumer Cyclical Risk 33 · Moderate
Price$0.96
Model IV—
P/IV—
Market implies -11.0%/yr vs model +2.0% · below model
XXII
22nd Century Group, Inc.
Valuation N/A
Consumer Defensive Risk 33 · Moderate
Price$1.99
Model IV—
P/IV—
Market implies -30.0%/yr vs model +2.0% · below model
YAAS
Youxin Technology Ltd
Valuation N/A
Technology Risk 33 · Moderate
Price$1.39
Model IV—
P/IV—
Market implies +77.1%/yr vs model +2.0% · above model
YDES
YD Bio Ltd
Valuation N/A
Healthcare Risk 29 · Moderate
Price$4.00
Model IV—
P/IV—
Market implies +43.8%/yr vs model +30.6% · above model
YDKG
Yueda Digital Holding
Valuation N/A
Technology Risk 33 · Moderate
Price$0.83
Model IV—
P/IV—
Market implies -50.0%/yr vs model +25.0% · below model
YJ
Yunji Inc.
Valuation N/A
Consumer Cyclical Risk 26 · Moderate
Price$1.99
Model IV—
P/IV—
Market implies +71.1%/yr vs model +2.0% · above model
YMM
Full Truck Alliance Co. Ltd.
Valuation N/A
Technology Risk 34 · Moderate
Price$8.17
Model IV—
P/IV—
Market implies +49.9%/yr vs model +21.1% · above model
YMT
Yimutian Inc.
Valuation N/A
Technology Risk 37 · Moderate
Price$2.24
Model IV—
P/IV—
Market implies +54.0%/yr vs model +15.0% · above model
YOU
Clear Secure, Inc.
Valuation N/A
Technology
Price$42.23
Model IV—
P/IV—
Limited data — see page
YQ
17 Education & Technology Group Inc.
Valuation N/A
Consumer Defensive Risk 31 · Moderate
Price$3.76
Model IV—
P/IV—
Market implies +62.1%/yr vs model +2.0% · above model
YRD
Yiren Digital Ltd.
Valuation N/A
Financial Services Risk 55 · Elevated
Price$1.01
Model IV—
P/IV—
Market implies -36.7%/yr vs model +3.9% · below model
YSG
Yatsen Holding Ltd
Valuation N/A
Consumer Defensive Risk 31 · Moderate
Price$2.58
Model IV—
P/IV—
Market implies +38.1%/yr vs model +2.0% · above model
YYAI
AIRWA INC.
Valuation N/A
Technology Risk 37 · Moderate
Price$0.73
Model IV—
P/IV—
Market implies -4.7%/yr vs model +15.0% · below model
ZBIO
Zenas BioPharma, Inc.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$31.12
Model IV—
P/IV—
Market implies +92.3%/yr vs model +2.0% · above model
ZEPP
Zepp Health Corp
Valuation N/A
Technology Risk 55 · Elevated
Price$4.58
Model IV—
P/IV—
Market implies +28.3%/yr vs model +2.0% · above model
ZETA
Zeta Global Holdings Corp.
Valuation N/A
Technology Risk 46 · Elevated
Price$31.01
Model IV—
P/IV—
Market implies +81.3%/yr vs model +24.5% · above model
ZJYL
Jin Medical International Ltd.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$2.07
Model IV—
P/IV—
Market implies +54.5%/yr vs model +2.0% · above model
ZKIN
ZK International Group Co., Ltd.
Valuation N/A
Industrials Risk 31 · Moderate
Price$1.12
Model IV—
P/IV—
Market implies +69.8%/yr vs model +2.0% · above model
ZLAB
Zai Lab Ltd
Valuation N/A
Healthcare Risk 42 · Elevated
Price$24.14
Model IV—
P/IV—
Market implies +37.3%/yr vs model +33.5% · above model
ZNTL
Zentalis Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$3.51
Model IV—
P/IV—
Market implies +22.0%/yr vs model +15.0% · above model
ZONE
CleanCore Solutions, Inc.
Valuation N/A
Consumer Defensive Risk 27 · Moderate
Price$0.15
Model IV—
P/IV—
Market implies +47.3%/yr vs model +29.2% · above model
ZSQR
Z Squared Inc.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$3.07
Model IV—
P/IV—
Market implies +15.3%/yr vs model +50.0% · below model
ZUMZ
Zumiez Inc
Valuation N/A
Consumer Cyclical Risk 44 · Elevated
Price$14.55
Model IV—
P/IV—
Market implies +21.1%/yr vs model +2.3% · above model